High-dose bolus tirofiban versus low-dose bolus in patients with acute coronary syndrome undergoing percutaneous coronary intervention

---

Atıf İçin Kopyala

ULUS T., Senol U., Tahmazov S., Iskenderov K., MUTLU F., ÇAVUŞOĞLU Y.

TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, cilt.45, sa.2, ss.126-133, 2017 (ESCI)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 45 Sayı: 2
• Basım Tarihi: 2017
• Doi Numarası: 10.5543/tkda.2016.92186
• Dergi Adı: TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY
• Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
• Sayfa Sayıları: ss.126-133
• Anahtar Kelimeler: Acute coronary syndromes, anti-platelet drugs, bleeding, tirofiban, ELEVATION MYOCARDIAL-INFARCTION, ANGIOPLASTY, ABCIXIMAB, INFUSION, THERAPY
• Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Aim of the present study was to determine effects of high-dose versus low-dose intravenous (IV) bolus tirofiban on angiographic measures, ST resolution, enzymatic infarct size, and clinical outcomes in patients with acute coronary syndrome (ACS) who were undergoing percutaneous coronary intervention (PCI) and received current pharmacoinvasive therapy.